 Doxorubicin
"Doxorubicin" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Antineoplastic antibiotic obtained from Streptomyces peucetius. It is a hydroxy derivative of DAUNORUBICIN.
| Descriptor ID |
D004317
|
| MeSH Number(s) |
D02.455.426.559.847.562.050.200.175 D04.615.562.050.200.175 D09.408.051.059.200.175
|
| Concept/Terms |
Doxil- Doxil
- Ortho Biotech Brand of Doxorubicin Hydrochloride
Doxorubicin NC- Doxorubicin NC
- Neocorp Brand of Doxorubicin Hydrochloride
Doxotec- Doxotec
- Columbia Brand of Doxorubicin Hydrochloride
Farmiblastina- Farmiblastina
- Kenfarma Brand of Doxorubicin Hydrochloride
Myocet- Myocet
- Elan Brand of Doxorubicin Hydrochloride
Onkodox- Onkodox
- Onkoworks Brand of Doxorubicin Hydrochloride
Ribodoxo- Ribodoxo
- ribosepharm Brand of Doxorubicin Hydrochloride
Rubex- Rubex
- Bristol-Myers Squibb Brand of Doxorubicin Hydrochloride
Adriblastin- Adriblastin
- Pfizer Brand of Doxorubicin Hydrochloride
- Adriblastina
- Adriblastine
- Adriablastin
- Adriablastine
Adriamycin- Adriamycin
- Bedford Brand of Doxorubicin Hydrochloride
Adrimedac- Adrimedac
- medac Brand of Doxorubicin Hydrochloride
Caelyx- Caelyx
- Schering Brand of Doxorubicin Hydrochloride
- Schering-Plough Brand of Doxorubicin Hydrochloride
- Essex Brand of Doxorubicin Hydrochloride
DOXO-cell- DOXO-cell
- DOXO cell
- Urokit Doxo-cell
- Urokit Doxo cell
- cell pharm Brand of Doxorubicin Hydrochloride
Doxolem- Doxolem
- Lemery Brand of Doxorubicin Hydrochloride
|
Below are MeSH descriptors whose meaning is more general than "Doxorubicin".
Below are MeSH descriptors whose meaning is more specific than "Doxorubicin".
This graph shows the total number of publications written about "Doxorubicin" by people in this website by year, and whether "Doxorubicin" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1980 | 0 | 2 | 2 | | 1981 | 0 | 2 | 2 | | 1982 | 1 | 3 | 4 | | 1983 | 0 | 4 | 4 | | 1984 | 0 | 5 | 5 | | 1985 | 2 | 2 | 4 | | 1986 | 0 | 2 | 2 | | 1987 | 0 | 1 | 1 | | 1988 | 0 | 3 | 3 | | 1989 | 1 | 2 | 3 | | 1990 | 1 | 2 | 3 | | 1991 | 2 | 3 | 5 | | 1992 | 0 | 3 | 3 | | 1993 | 0 | 1 | 1 | | 1994 | 2 | 2 | 4 | | 1995 | 2 | 2 | 4 | | 1996 | 0 | 4 | 4 | | 1997 | 2 | 1 | 3 | | 1998 | 0 | 6 | 6 | | 1999 | 0 | 1 | 1 | | 2000 | 1 | 2 | 3 | | 2001 | 4 | 6 | 10 | | 2002 | 1 | 2 | 3 | | 2003 | 0 | 3 | 3 | | 2004 | 1 | 8 | 9 | | 2005 | 0 | 7 | 7 | | 2006 | 2 | 4 | 6 | | 2007 | 2 | 7 | 9 | | 2008 | 1 | 3 | 4 | | 2009 | 0 | 6 | 6 | | 2010 | 5 | 5 | 10 | | 2011 | 3 | 6 | 9 | | 2012 | 1 | 7 | 8 | | 2013 | 1 | 7 | 8 | | 2014 | 2 | 4 | 6 | | 2015 | 3 | 5 | 8 | | 2016 | 1 | 5 | 6 | | 2017 | 1 | 4 | 5 | | 2018 | 0 | 3 | 3 | | 2019 | 2 | 6 | 8 | | 2020 | 1 | 2 | 3 | | 2022 | 0 | 2 | 2 |
To return to the timeline, click here.
Below are the most recent publications written about "Doxorubicin" by people in Profiles.
-
Castellino SM, Pei Q, Parsons SK, Hodgson D, McCarten K, Horton T, Cho S, Wu Y, Punnett A, Dave H, Henderson TO, Hoppe BS, Charpentier AM, Keller FG, Kelly KM. Brentuximab Vedotin with Chemotherapy in Pediatric High-Risk Hodgkin's Lymphoma. N Engl J Med. 2022 11 03; 387(18):1649-1660.
-
Wu C, Hormuth DA, Lorenzo G, Jarrett AM, Pineda F, Howard FM, Karczmar GS, Yankeelov TE. Towards Patient-Specific Optimization of Neoadjuvant Treatment Protocols for Breast Cancer Based on Image-Guided Fluid Dynamics. IEEE Trans Biomed Eng. 2022 11; 69(11):3334-3344.
-
Buocikova V, Longhin EM, Pilalis E, Mastrokalou C, Miklikova S, Cihova M, Poturnayova A, Mackova K, Babelova A, Trnkova L, El Yamani N, Zheng C, Rios-Mondragon I, Labudova M, Csaderova L, Kuracinova KM, Makovicky P, Kucerova L, Matuskova M, Cimpan MR, Dusinska M, Babal P, Chatziioannou A, Gabelova A, Rund?n-Pran E, Smolkova B. Decitabine potentiates efficacy of doxorubicin in a preclinical trastuzumab-resistant HER2-positive breast cancer models. Biomed Pharmacother. 2022 Mar; 147:112662.
-
Mittendorf EA, Zhang H, Barrios CH, Saji S, Jung KH, Hegg R, Koehler A, Sohn J, Iwata H, Telli ML, Ferrario C, Punie K, Penault-Llorca F, Patel S, Duc AN, Liste-Hermoso M, Maiya V, Molinero L, Chui SY, Harbeck N. Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial. Lancet. 2020 10 10; 396(10257):1090-1100.
-
Association of Event-Free and Distant Recurrence-Free Survival With Individual-Level Pathologic Complete Response in Neoadjuvant Treatment of Stages 2 and 3 Breast Cancer: Three-Year Follow-up Analysis for the I-SPY2 Adaptively Randomized Clinical Trial. JAMA Oncol. 2020 09 01; 6(9):1355-1362.
-
Bellary A, Villarreal A, Eslami R, Undseth QJ, Lec B, Defnet AM, Bagrodia N, Kandel JJ, Borden MA, Shaikh S, Chopra R, Laetsch TW, Delaney LJ, Shaw CM, Eisenbrey JR, Hernandez SL, Sirsi SR. Perfusion-guided sonopermeation of neuroblastoma: a novel strategy for monitoring and predicting liposomal doxorubicin uptake in vivo. Theranostics. 2020; 10(18):8143-8161.
-
Oza AM, Matulonis UA, Alvarez Secord A, Nemunaitis J, Roman LD, Blagden SP, Banerjee S, McGuire WP, Ghamande S, Birrer MJ, Fleming GF, Markham MJ, Hirte HW, Provencher DM, Basu B, Kristeleit R, Armstrong DK, Schwartz B, Braly P, Hall GD, Nephew KP, Jueliger S, Oganesian A, Naim S, Hao Y, Keer H, Azab M, Matei D. A Randomized Phase II Trial of Epigenetic Priming with Guadecitabine and Carboplatin in Platinum-resistant, Recurrent Ovarian Cancer. Clin Cancer Res. 2020 03 01; 26(5):1009-1016.
-
Taparra K, Liu H, Polley MY, Ristow K, Habermann TM, Ansell SM. Bleomycin use in the treatment of Hodgkin lymphoma (HL): toxicity and outcomes in the modern era. Leuk Lymphoma. 2020 02; 61(2):298-308.
-
Lin S, Yu L, Song X, Bi J, Jiang L, Wang Y, He M, Xiao Q, Sun M, Olopade OI, Zhao L, Wei M. Intrinsic adriamycin resistance in p53-mutated breast cancer is related to the miR-30c/FANCF/REV1-mediated DNA damage response. Cell Death Dis. 2019 09 11; 10(9):666.
-
Sasaki K, Ishihara J, Ishihara A, Miura R, Mansurov A, Fukunaga K, Hubbell JA. Engineered collagen-binding serum albumin as a drug conjugate carrier for cancer therapy. Sci Adv. 2019 08; 5(8):eaaw6081.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|